Media Coverage

Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs

Xconomy

Media Coverage

Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement

ADC Review

Media Coverage

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001

ADC Review

Media Coverage

Randall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics

ADC Review

Media Coverage

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy

ADC Review

Media Coverage

Bolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor’s New Idea Deeper in the Clinic

Endpoints News

Media Coverage

Bolt’s Myeloid Twist on ADCs Charged up with $93.5M series C

BioCentury

Media Coverage

Pfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med Hits the Clinic

Fierce Biotech

Media Coverage

Agonist ecstasy? HER2 (and more) ‘Bolt’-on strategy draws $93.5M series C

BioWorld

Media Coverage

Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors

Precision Oncology News